ProfileGDS5678 / 1435364_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 52% 52% 53% 52% 50% 50% 52% 52% 52% 41% 53% 59% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2841951
GSM967853U87-EV human glioblastoma xenograft - Control 23.2651252
GSM967854U87-EV human glioblastoma xenograft - Control 33.2623652
GSM967855U87-EV human glioblastoma xenograft - Control 43.2358453
GSM967856U87-EV human glioblastoma xenograft - Control 53.2252
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2868350
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2621250
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2422852
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2444152
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2564552
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9250741
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2478753
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5763359
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4313857